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Most evaluations of screening do not include the full
range of benefits and harms.1 2 The United Kingdom
and World Health Organization’s latest guidelines on
screening accentuate the need for more rigorous
evidence of effectiveness and greater concern about
the adverse effects of subsequent investigation and
management.3 4 The UK guidelines now state that the
benefit from the screening programme should
outweigh the physical and psychological harm caused
by the test, diagnostic procedures, and treatment.3 In
the updated WHO guidelines for medical screening,
Strong et al state that “Identification of either trivial or
untreatable conditions can cause anxiety and waste
resources with no practical outcome.”4 They also argue
that the acceptability of screening is an important issue
to consider. We outline three principles concerned
with how consumers’ views can be ascertained and
used to enable value based decisions about screening
programmes.

Value all benefits and harms
Evidence from randomised trials that screening
reduces mortality is necessary but not sufficient to justify screening. Decisions should be based on an assessment of all the benefits and harms, not only of the
screening test but also of follow up tests and
treatments. As the UK criteria state, the screening programme must be clinically, socially, and ethically
acceptable to the public and the benefits outweigh the
harm.3
A holistic approach to evaluation requires studies
to identify the benefits and harms perceived by
consumers and clinicians. Harms include:
x Complications of investigation of screen detected
abnormalities
x Unexpected effects, such as increased morbidity and
mortality from side effects of screening or subsequent
management
x Overdetection—the identification of disease that
would not have presented during the person’s lifetime,
and
x Psychosocial effects.
Some harms or downsides may seem trivial, but,
unlike the benefits, occur soon after screening and are

common. For example, biennial mammographic
screening has been estimated to avert only two deaths
in 1000 women aged 50-59 over 10 years but requires
5000 screens, 242 recalls, and 64 women to have at
least one biopsy.5 Moreover, five women will have a
ductal carcinoma in situ detected, some of which may
never have progressed if left untreated. This information may lead some people to decide that the
downsides of screening outweigh avoidance of longer
term serious but rare outcomes.6
Consultation about screening policy between
policy makers and an informed public is essential.
The public can be involved through methods such as
citizen juries, deliberative panels, and round table
discussions with community members.7 Community
surveys among representative samples can provide
policy makers with useful information about how
benefits are valued against harms in the population.6 8 9 Preferences can be measured directly: “Given
the benefits and harms, would you prefer to be
screened or not screened?” or through utility
measurement techniques that assess individuals’
preferences through specific trades or gambles
(choices) associated with the benefits and harms of
screening.
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Enable participation in informed choice
High quality evidence that a reasonable proportion of
consumers would see the benefits as outweighing the
harms may be sufficient to decide to offer screening.
However, some consumers may still not want to be
screened.6 9
Patient autonomy requires that people should be
able to choose, free from coercion, whether they wish
to participate in screening. To make a decision participants require unbiased information on both the
benefits as well as the harms of screening.10 However,
although there have been some encouraging moves in
this direction,11 12 much current information overemphasises the benefits of screening, minimises the
harms, and does not clarify to the reader that there is a
choice to be made about whether screening is
worthwhile for them.13 14 Consequently, informed
choice is difficult to achieve and screening has
overwhelming uncritical public support.15
Consumers, and their practitioners, should therefore receive balanced information about the benefits
and harms of screening. Including information about
how similar people weigh the benefits and harms—for
example, data from surveys of community
preferences—may also be helpful. Individuals then
have different ways of exercising informed choice
about screening. They may follow screening guidelines
provided by an authoritative health body or their doctor’s advice, or they may weigh up the benefits and
harms for their personal situation. People who want to
make an individual decision may require more detailed
information than initially given.
Tools to support consumers in making informed
decisions about their health care, such as decision aids,
have been shown to improve knowledge, clarify
preferences, and reduce uncertainty around decision
making, with high levels of acceptability among
consumers.10 16 Further development and research is
needed to ensure that these tools are easy to understand
and use by all sectors of the community and do not create barriers that contribute to social inequity.

Measure concordance between
preferences and actions
Providers need to select performance indicators for
screening that fit with the consumer choice model.17
Participation rates, often used as one of the markers of
success of screening programmes, are not an adequate
marker of appropriate participation. Indeed, when
they are accompanied by incentive payments to practitioners (such as in the UK and Australian cervical
screening programmes) they may undermine the provision of genuine choice to consumers.18 19
Some providers have been reluctant to allow
consumer choice. This may partly derive from the
common misconception that a high participation rate
is necessary to ensure community benefit and cost
effectiveness. But in most cases community benefit is
no more than the sum of the individual benefits, the
main exception being screening for infectious diseases
such as tuberculosis. If the screening programmes do
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not have large set-up costs, benefits are usually proportional to costs.20 For colorectal cancer screening, cost
effectiveness has been shown to worsen only at
extremely low levels of participation.21
The measurement of appropriate participation in
screening is challenging.17 22 Marteau and colleagues
have developed a measure of informed choice for use
in prenatal testing based on the constructs knowledge,
attitudes, and behaviour.22 Jepson proposes a more
complex set of factors to indicate informed choice in
cancer screening programmes.17 Dowie also outlines a
model based on decision responsibility, information
provision and value clarification.23
We propose a simple three stage model for use in
screening that assesses the consistency between an
individual’s preference for decision making and their
subsequent screening behaviour. This approach
recognises that not all consumers will want to make an
individually based choice and highlights the relation
between the decision about screening (intentions) and
subsequent screening behaviour. The model proposes
that all those eligible for screening should be aware of
the screening programme and have received and
understood an agreed minimum of information about
benefits and harms of the procedure so that they can
decide whether to follow the advice of an authoritative
health body or make an individual choice. Secondly,
everyone should know how to access the information
and support to make a personal decision about
screening. Thirdly, there should be an assessment of
the extent to which an individual’s screening
intentions and behaviour agree with his or her
preferred method of decision making. For consumers
who prefer to follow advice, we would expect that their
decisions and behaviour are consistent with the
recommendation. For consumers who prefer to make
an individual choice, we would expect the consumer
who chooses to be screened to perceive the benefits of
screening as outweighing the harms and vice versa for
those who choose not to be screened.
Tools need to be developed to measure both
intentions and behaviour. The match between them
provides valuable feedback to indicate whether genuine
choice is on offer. If consumers intend to be screened
but are not, this suggests that there are obstacles to participation. On the other hand, if consumers do not
intend to be screened but are, this may indicate lack of
choice. Evaluation needs to include assessment of
whether the provision of understandable information
and access to choice and decision support is equal to all,
irrespective of social, economic, or cultural factors. In
this way, fairness is achieved not by maximising
participation but by ensuring that everyone has an equal
opportunity to make an informed choice.

Conclusion
The three principles described above have implications
for decisions about whether screening should be
introduced and, once introduced, how it should be
evaluated. The consumer should be at the centre of the
value based principles. Health professionals and policy
makers need to provide the means to enable this. A
1149
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Summary points

3

All benefits and harms of screening must be fully
ascertained and undergo community valuation
before screening is offered

4

5

Service providers should respect patient
autonomy and ensure that participation in
screening is an informed choice
Concordance between consumer preferences and
screening behaviour should replace participation
as one of the measures of success for screening
programmes

6
7

8
9

10

more holistic approach to evaluation, respect for
consumer autonomy in decision making, and pursuit of
informed choice in screening should lead to better
benefit:harm ratios and improve the framework for
assessing the worth of population screening programmes.
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The human genome map has started a hunt to find common genes that are associated with cancer.
But new research questions the likelihood of success.
Huge resources are being invested in the search for
common inherited genetic variants that increase
susceptibility to cancer. However, these studies are
expensive because they require large sample sizes to
rule out false positive results (table).1 2 The US cancer
genetic markers of susceptibility project (http://
cgems.cancer.gov), for example, will cost $14m (£7.9m;
€11m). In addition, large replication studies may still be
necessary to confirm generalisability to other popula-

tions. For these studies to eventually lead to a clinical
therapeutic benefit, common genetic variants that
increase susceptibility to cancer must exist and it must
be feasible to rigorously evaluate the clinical benefit of
targeting these common genetic variants. Both these
requirements require formal consideration.
An explanation of sample size calculations for gene-cancer
association studies is on bmj.com
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